Novartis to File for COPD Treatment QVA149 in Japan, EU by End of 2012

Novartis AG of Switzerland announced on August 30 that it will submit the chronic obstructive pulmonary disease (COPD) treatment QVA149 (indacaterol maleate + glycopyrronium bromide) for approval in Japan and Europe by the end of this year. The company expects...read more